pegloticase trade name krystexxa medication treatment severe treatmentrefractory chronic gout third line treatment treatments drug administered infusion intravenously developed savient approved united states two clinical trials found lowered uric acid levels reduced deposits uric acid crystals joints soft tissue european medicines agency ema granted marketing authorization treatment disabling tophaceous gout authorization ended option people gout intolerant pegloticase given intravenous infusion every two found reduce uric acid levels moderate quality evidence useful tophi high rate side effects withdrawals due adverse people develop resistance medication individuals dehydrogenase deficiency pegloticase may precipitate severe lifethreatening hemolysis methemoglobinemia therefore contraindicated individuals pegloticase may also show pegloticase recombinant porcinelike uricase similarly rasburicase metabolises uric acid allantoin reduces risk precipitates since allantoin five ten times soluble uric acid contrast rasburicase pegloticase pegylated increase elimination halflife eight hours ten twelve days decrease immunogenicity foreign uricase protein modification allows dosing interval two four weeks increasing suitability longterm pegloticase tetrameric protein composed four identical chains amino acids approximately nine lysine residues chain pegylated peg chains consist ethylene glycol units kgmol httpsenwikipediaorgwikipegloticase